doxazosin has been researched along with Idiopathic Parkinson Disease in 2 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate predictors of the response to doxazosin, a selective alpha-adrenoceptor antagonist, when used for the treatment of lower urinary tract symptoms in men with Parkinson's disease." | 5.19 | Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. ( Barbosa, ER; Bessa Junior, Jd; Bruschini, H; Gomes, CM; Lopes, RI; Nitti, VW; Sallem, FS; Sammour, ZM; Srougi, M; Trigo-Rocha, FE, 2014) |
| " Additional dose-response analyses were carried out." | 1.62 | Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simmering, JE | 1 |
| Welsh, MJ | 1 |
| Liu, L | 1 |
| Narayanan, NS | 1 |
| Pottegård, A | 1 |
| Gomes, CM | 1 |
| Sammour, ZM | 1 |
| Bessa Junior, Jd | 1 |
| Barbosa, ER | 1 |
| Lopes, RI | 1 |
| Sallem, FS | 1 |
| Trigo-Rocha, FE | 1 |
| Bruschini, H | 1 |
| Nitti, VW | 1 |
| Srougi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for doxazosin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Antiparkinson Agents; Doxazosin; Humans; Lower | 2014 |
1 other study available for doxazosin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, | 2021 |